Arena Pharmaceuticals downgraded by Cantor Fitzgerald with a new price target

12/21/21 5:12:52 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Cantor Fitzgerald downgraded Arena Pharmaceuticals from Overweight to Neutral and set a new price target of $100.00 from $93.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ARNA

Date	Price Target	Rating	Analyst
2/9/2022	$120.00 → $100.00	Buy → Neutral	HC Wainwright & Co.
12/21/2021	$93.00 → $100.00	Overweight → Neutral	Cantor Fitzgerald
12/14/2021		Market Outperform → Market Perform	JMP Securities
12/14/2021	$112.00 → $100.00	Outperform → Market Perform	SVB Leerink
12/14/2021	$76.00 → $100.00	Outperform → Sector Perform	RBC Capital
12/14/2021	$98.00 → $100.00	Outperform → Neutral	Credit Suisse
12/14/2021	$100.00	Buy → Hold	Jefferies
12/13/2021		Buy → Hold	Needham